InMed PharmaceuticalsINM -0.61%29 Return-on-Tangible-Equity is -176.51% as of Mar. 2026. GuruFocus rates INM with a GF Score™ of 29/100 and a GF Value™ of $0.93 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 897 Drug Manufacturers companies, InMed Pharmaceuticals ranks worse than 95.65% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. InMed Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was $-11.86 Mil. InMed Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $6.72 Mil. Therefore, InMed Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -176.51%.
The historical rank and industry rank for InMed Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
INM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -280.02 Med: -92.88 Max: -52.39
Current: -104.72
During the past 13 years, InMed Pharmaceuticals's highest Return-on-Tangible-Equity was -52.39%. The lowest was -280.02%. And the median was -92.88%.
INM's Return-on-Tangible-Equity is ranked worse than 95.65% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs INM: -104.72
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
InMed Pharmaceuticals Return-on-Tangible-Equity Related Terms
InMed Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for InMed Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INM vs SNOA, CVSI, PRFX: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InMed Pharmaceuticals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -176.51% mean?
InMed Pharmaceuticals (INM) has a Return-on-Tangible-Equity of -176.51% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on InMed Pharmaceuticals and its competitors. According to the industry distribution chart, InMed Pharmaceuticals ranks #858 out of 897 companies in the Drug Manufacturers industry, placing it in the top 95.7%.
Is InMed Pharmaceuticals' Return-on-Tangible-Equity too high?
InMed Pharmaceuticals' current Return-on-Tangible-Equity is -176.51%. Based on the distribution chart, InMed Pharmaceuticals ranks #858 out of 897 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Return-on-Tangible-Equity compare to SNOA and CVSI?
According to the Drug Manufacturers industry distribution chart, InMed Pharmaceuticals ranks #858 out of 897 companies for Return-on-Tangible-Equity. This places InMed Pharmaceuticals in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on InMed Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InMed Pharmaceuticals's current Return-on-Tangible-Equity is -176.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, InMed Pharmaceuticals (INM) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.93, compared to a current price of $1.65 — trading 77.4% above its estimated fair value. The current Return-on-Tangible-Equity is -176.51%. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current Return-on-Tangible-Equity is -176.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InMed Pharmaceuticals (INM) Overvalued in 2026?
Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued.
The current stock price of $1.65 is trading 77.4% above its estimated GF Value™ of $0.93.
GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INM:
Return-on-Tangible-Equity: -176.51%
GF Value™: $0.93 vs. price of $1.65 (77.4% above fair value)
No single metric tells the full story. See the INM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score
Get the complete analysis for INM
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INM has been successfully added to your 
